||Recombinant Human NCAM1 (Accession # NP_001070150) was produced in Mouse myeloma cell line, NS0-derived.
|Predicted N Terminal:
||Lyophilized from a 0.2 µm filtered solution in Tris and NaCl.
||Measured by the ability of the immobilized protein to support the adhesion of Neuro-2A mouse neuroblastoma cells.When 5 x 10^4 cells/well are added to recombinant human NCAM-1 coated plates, cell adhesion is enhanced in a dose dependent manner after 1 hour incubation at 37 °C. The ED50 for this effect is typically 0.5 - 3 µg/mL. Optimal dilutions should be determined by each laboratory for each application.
||Recombinant Human NCAM1 has a calculated MW of 76.5 kDa. In SDS-PAGE migrates as 120 kDa, reducing conditions.
||>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).